TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23123509
Drug: nab-P/C (nab-paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-P/C (nab-paclitaxel 100 mg/m² weekly)
Study: 23123509
Drug: sb-P/C (solvent-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: sb-P/C (solvent-based paclitaxel 200 mg/m² day 1 every 3 weeks)
Study: 11123451
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution
Study: 9463082
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of serum IgG class anti-CMV antibodies in women following spontaneous abortions (n=11)
Study: 9463082
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of serum IgG class anti-HPV-B19 antibodies in women following spontaneous abortions (n=11)
Study: 9463082
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of IgM and IgG class antibodies against CMV and HPV-B19 in one patient
Study: 2195714
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg q.i.d. for 28 days)
Study: 2195714
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablets for 28 days)
Study: 29777529
Drug: ADS-5102 (210,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADS-5102 (210, 274, or 338 mg)
Study: 28203003
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (medication group, low dose aspirin)
Study: 15090564
Drug: Subcutaneous IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IFN beta‐1a, 22 micro g once weekly
Study: 11715631
Drug: Rob 10
Normalized name: carob 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rob 10 (3 x 25 drops daily)
Study: 8087826
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion for 24 hours
Study: 8087826
Drug: N-acetylcysteine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine administration after nitroglycerin infusion
Study: 31370954
Drug: RAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitors
Study: 25345681
Drug: Daily sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sessions of music-guided slow-breathing (<10 breaths/min) for 30 minutes
Study: 18623908
Drug: Maraviroc (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (300 mg twice a day)
Study: 12640507
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 to 4 mg/day)
Study: 12640507
Drug: Captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75 to 150 mg/day)
Study: 1831633
Drug: Ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.15 mg/kg, three intravenous doses 4-hourly)
Study: 1831633
Drug: Metoclopramide (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (2.0 mg/kg, six intravenous doses)
Study: 1831633
Drug: Oral Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Ondansetron (16 mg t.d.s.)
Study: 6346845
Drug: Ethmozine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethmozine (mean total daily dose of 830 mg +/- 318 mg, dosing every 8 hours)
Study: 18682410
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml ropivacaine 0.5%
Study: 18682410
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml ropivacaine 0.5%
Study: 27396224
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg/kg (Group K, n = 91)
Study: 22143524
Drug: Tigecycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100 mg loading dose followed by 50 mg every 12 h for a minimum of 7 days)
Study: 9571385
Drug: ASPD+ (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASPD+ (180 days treatment)
Study: 9571385
Drug: AABS+ (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: AABS+ (180 days treatment)
Study: 9571385
Drug: ASPD+ (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASPD+ (90 days treatment)
Study: 9571385
Drug: AABS+ (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AABS+ (90 days treatment)
Study: 26014295
Drug: Androgen-deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-deprivation therapy (ADT) with radiotherapy (RT)
Study: 22008927
Drug: Daily media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily media habits of smokers
Study: 17892034
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal hormonal therapy with 17beta‐estradiol (0.05 mg/24 hours) and oral dydrogesterone (5 mg daily)
Study: 17892034
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal hormonal therapy with 17beta‐estradiol (0.05 mg/24 hours) and oral medroxyprogesterone (5 mg daily)
Study: 9459623
Drug: Euthyroid at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euthyroid at drug withdrawal
Study: 7491892
Drug: Fried onions
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fried onions (rich in quercetin glucosides) equivalent to 89 mg aglycone
Study: 7491892
Drug: Pure quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure quercetin rutinoside equivalent to 100 mg aglycone
Study: 7491892
Drug: Pure quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure quercetin aglycone equivalent to 100 mg
Study: 2128072
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EDTA and sugar tests
Study: 31228675
Drug: Intravenous intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous intralipid (2 doses of 20% solution, 4 ml diluted in 250 ml normal saline)
Study: 24742182
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at local acupoints in combination with distal acupoint
Study: 24742182
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at local acupoints in combination with distal non-acupoint
Study: 24742182
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at local non-acupoints in combination with distal acupoint
Study: 24742182
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at local non-acupoints in combination with distal non-acupoint
Study: 20097934
Drug: Dapoxetine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine (single and multiple dosing)
Study: 19068724
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of epirubicin (40 mg in 40 ml saline) once every two weeks for 3 months starting one week after TURBT (Group A)
Study: 19068724
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of epirubicin (40 mg in 40 ml saline) once every two weeks for 3 months starting 6 months after TURBT (Group B)
Study: 15854872
Drug: Reformulated cognitive-behavioral
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated cognitive-behavioral (RCB) treatment
Study: 15854872
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral (SB) treatment
Study: 12814527
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) 3 mg vaginal pessary in two doses 6 hourly
Study: 12814527
Drug: Extra-amniotic saline
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic saline infusion (EASI) with simultaneous intravenous oxytocin infusion for 12 hours
Study: 2246997
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine preparation
Study: 2246997
Drug: Clonidine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (oral or transdermal)
Study: 7425917
Drug: 1 drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of the optimal combination
Study: 7425917
Drug: 2 drops
Normalized name: CHOLECALCIFEROL 12.5 ug in 0.04 mL / MENAQUINONE 7 50 ug in 0.04 mL ORAL SOLUTION/ DROPS [YYUX Organic Liquid Vitamin D3 plus K2 Drops]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 drops of the optimal combination
Study: 25557838
Drug: Zanamivir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir (10 mg daily prophylaxis)
Study: 25557838
Drug: Trivalent split
Normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent split virus influenza vaccine
Study: 25557838
Drug: Both zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Both zanamivir and vaccine
Study: 19330567
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron sulphate
Study: 11465336
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of placebo gel (Group I)
Study: 11465336
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2% lidocaine gel (Group II)
Study: 11465336
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 2% lidocaine gel (Group III)
Study: 9766721
Drug: Endorectal coil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endorectal coil (ERC) at 60, 100, and 140 ml balloon inflation
Study: 8143427
Drug: Fed state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed state (after a meal containing 80 g of fat and 80 g of carbohydrate)
Study: 2974418
Drug: 5'dFUR (doxifluridine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'dFUR (doxifluridine) 2 g.m-2
Study: 2974418
Drug: 5'dFUR (doxifluridine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'dFUR (doxifluridine) 4 g.m-2
Study: 30102652
Drug: Fluconazole 1200 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 1200 mg/day
Study: 24901857
Drug: MPSS alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPSS alone (30 mg/kg initially and 5.4 mg/kg every hour till 23 hours if admitted within 3 hours and till 47 hours if recruited within 3-6 hours)
Study: 18926059
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg twice a day for 6 weeks)
Study: 16408169
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac suppository
Study: 28783865
Drug: Capsule A
Normalized name: capsule administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule A (4 mg)
Study: 28783865
Drug: Capsule B
Normalized name: Emend 80mg Capsule BiPack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule B (4 mg)
Study: 27310949
Drug: Lowest TA-SUA
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest TA-SUA group (<5.5 mg/dL)
Study: 27310949
Drug: Middle 3
Normalized name: WHEAT MIDDLINGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle 3 TA-SUA groups (5.5-8.4 mg/dL)
Study: 27310949
Drug: Highest TA-SUA
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest TA-SUA group (≥8.5 mg/dL)
Study: 22718556
Drug: 0.4 µg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 µg/kg/min PGE(2) (Prostin(®)E2, dinoprostone)
Study: 16989901
Drug: Ruboxistaurin (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruboxistaurin (32 mg/day)
Study: 16353319
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta‐E2/0.5 mg NETA
Study: 16353319
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17beta‐E2/1 mg NETA
Study: 9786602
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (nisoldipine or benidipine)
Study: 9786602
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (ACEI) (captopril or imidapril)
Study: 9786602
Drug: Beta-receptor blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-receptor blockers (arotinolol or bisoprolol)
Study: 9786602
Drug: All antihypertensive
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antihypertensive agents
Study: 7665814
Drug: Current medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current medical therapy for severe ulcerative colitis
Study: 7665814
Drug: Current medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current medical therapy for severe Crohn's colitis
Study: 29164377
Drug: 3.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.25 mg/day DHEA
Study: 29164377
Drug: 6.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg/day DHEA
Study: 25194884
Drug: beclomethasone/formoterol (100/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone/formoterol (100/6 μg) bid
Study: 25194884
Drug: budesonide/formoterol (160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol (160/4.5 μg) bid
Study: 17581531
Drug: sustained‐release bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained‐release bupropion 150 mg twice daily
Study: 17121524
Drug: l-thyroxine (low-TSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-thyroxine (low-TSH group, 13 patients)
Study: 17121524
Drug: l-thyroxine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-thyroxine plus placebo (euthyroidism group, 12 patients)
Study: 10807468
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g vitamin C (single dose)
Study: 10807468
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g vitamin C daily for 8 weeks
Study: 8632572
Drug: 10.8 mg
Normalized name: goserelin 10.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8 mg goserelin depot, administered every 12 weeks
Study: 8632572
Drug: 3.6 mg
Normalized name: menthol 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg goserelin depot, administered every 4 weeks
Study: 8632572
Drug: 10.8 mg
Normalized name: goserelin 10.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8 mg goserelin depot
Study: 6402355
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cellulose bound nitroglycerin
Study: 6402355
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cellulose bound nitroglycerin
Study: 30633722
Drug: Belatacept infusions
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belatacept infusions
Study: 19561259
Drug: Drip infusion
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip infusion for VCUG
Study: 14647133
Drug: Sustained-release oxycodone
Normalized name: oxycodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oxycodone (CRO)
Study: 14647133
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine (CRM)
Study: 14647133
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine and oxycodone
Study: 10756544
Drug: Alginate gel
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate gel beads prepared with low molecular size alginate
Study: 10756544
Drug: Alginate gel
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate gel beads (general)
Study: 10756544
Drug: Commercial sustained-release
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial sustained-release tablet (Carvisken)
Study: 8930425
Drug: Ceftibuten oral
Normalized name: ceftibuten Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten oral suspension 9 mg/kg once daily (maximum dose, 400 mg/d) for 10 days
Study: 8930425
Drug: Cefprozil oral
Normalized name: cefprozil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil oral suspension 15 mg/kg twice daily (maximum dose, 1000 mg/d) for 10 days
Study: 1473854
Drug: Modified Release
Normalized name: MODIFIED RELEASE CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Release (MR) formulation of diltiazem (60 mg)
Study: 1473854
Drug: Modified Release
Normalized name: MODIFIED RELEASE CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Release (MR) formulation of diltiazem
Study: 1473854
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) formulation of diltiazem (60 mg)
Study: 2865156
Drug: Beta-adrenoceptor blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoceptor blocker (propranolol)
Study: 2865156
Drug: Combined alpha-
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined alpha- and beta-adrenoceptor blocker (labetalol)
Study: 27630373
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg or 1.0 mg administered at tumor localization and every 2 months for 24 months
Study: 19068079
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg delta(9)-THC
Study: 19068079
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg delta(9)-THC
Study: 19068079
Drug: delta(9)-THC with
Normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: delta(9)-THC with SR141716A (CB(1) receptor antagonist)
Study: 27175657
Drug: EALM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EALM therapy (esomeprazole 40 mg bid and amoxicillin 1 g bid for 5 days, followed by esomeprazole 40 mg bid, levofloxacin 500 mg qd, and metronidazole 500 mg tid, for 5 days)
Study: 27175657
Drug: 10-day EAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day EAL therapy (levofloxacin 500 mg qd, amoxicillin 1 g bid, and esomeprazole 40 mg bid)
Study: 20840223
Drug: Supervised implementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised implementation of the oral health care guideline
Study: 18596969
Drug: HPC containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPC containing 0.03% FGF-2 (Group L)
Study: 16858953
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (aspirin 300 mg/d + dipyridamole 75 mg thrice a day)
Study: 16858953
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (300 mg/d)
Study: 10638394
Drug: 5-mg oral
Normalized name: Augmentin 875-mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg oral doses of amlodipine (reference formulation)
Study: 10638394
Drug: 5-mg oral
Normalized name: Augmentin 875-mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg oral doses of amlodipine (test formulation)
Study: 1788636
Drug: Ultra-high streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-high streptokinase therapy
Study: 1788636
Drug: Conventional streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional streptokinase dosage
Study: 7270985
Drug: Weekly injections
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injections of ragweed antigen
Study: 7270985
Drug: Monthly injections
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly injections of ragweed antigen
Study: 30672255
Drug: Herb-separated moxibustion
Normalized name: serrated swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herb-separated moxibustion combined with sulfasalazine enteric-coated tablets
Study: 30672255
Drug: Conventional moxibustion
Normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional moxibustion combined with sulfasalazine enteric-coated tablets
Study: 24112528
Drug: Blood (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood (1 mL)
Study: 21044117
Drug: Aldosterone levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone levels before adrenalectomy (235.0 ± 51.1 pg/ml)
Study: 16547688
Drug: Calcitriol treatment
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol treatment (1 microg/day for 7 days)
Study: 12968960
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (4 ml) applied to wound surfaces and under the flap
Study: 11068889
Drug: Child-alone cognitive-behavioral
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-alone cognitive-behavioral treatment
Study: 11068889
Drug: Family cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family cognitive-behavioral treatment
Study: 7731155
Drug: Nonionic contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic contrast agent (iohexol)
Study: 3882619
Drug: Ionic contrast
Normalized name: IONIC CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic contrast agent (sodium methylglucamine diatrizoate)
Study: 30994776
Drug: In‐office bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: In‐office bleaching with 35% HP and one application of placebo gel (20 minutes), followed by at‐home bleaching with 10% CP (2 hours/day for 16 days)
Study: 26990892
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose melphalan followed by autologous transplantation (HDM/ASCT)